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Résumé en
anglais
Pneumocystis jirovecii is a transmissible fungus with a high pulmonary tropism. The
prevalence of P. jirovecii in patients with cystic fibrosis (CF) has been estimated in
Germany at 7.4%, in Spain at 21.5% and in Brazil at 38.2%. Data on the prevalence of
P. jirovecii in CF patients in France remain scarce, particularly in Brittany, where the
prevalence of CF is high (from 1/1600 to 1/4500). Our objectives were to determine
the prevalence of colonization of the airways by P. jirovecii in Brittany in CF patients
monitored at the "Centre de Ressources et de Compétences de la Mucoviscidose
(CRCM)" of Rennes compared to that previously observed at the CRCM of Roscoff-
Brest. Sputa from 86 patients (178 specimens) followed in Rennes were analyzed
retrospectively. The detection of P. jirovecii was performed using real-time PCR
targeting the gene encoding the mitochondrial large subunit of ribosomal RNA.
Pneumocystis jirovecii DNA was detected in 3/86 patients (3.5%) monitored at
Rennes, whereas it had previously been detected in 1/76 patients (1.3%) monitored at
Roscoff-Brest, thus showing an overall prevalence of 2.5% in Brittany. These results
obtained from two Breton centers taken together show that P. jirovecii prevalence in
patients with CF in Brittany is lower than those observed in Germany, Spain, Brazil or
in other regions of France. This study is a preliminary step in determining the risk
factors for P. jirovecii acquisition, its epidemiological and clinical significance in CF
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